Literature DB >> 9255555

Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.

B Burchell1, M W Coughtrie.   

Abstract

Glucuronidation and sulfation are phase 2 metabolic reactions catalyzed by large families of different isoenzymes in man. The textbook view that glucuronidation and sulfation lead to the production of harmless conjugates for simple excretion is not valid. Biologically active and toxic sulfates and glucuronides are produced and leed to adverse drug reactions, including immune hypersensitivity. Considerable variation in xenobiotic conjugation is observed as a result of altered expression of UDP-glucuronosyltransferases (UGTs) and sulfotransferases (STs). Recent cloning and expression of human cDNA encoding UGTs and STs has facilitated characterization of isoform substrate specificity, which has been further validated using specific antibodies and human tissue fractions. The availability of cloned/expressed human enzymes and specific antibodies has enabled the investigation of xenobiotic induction and metabolic disruption leeding to adverse responses. Genetic polymorphisms of glucuronidation and sulfation are known to exist although the characterization and assessment of the importance of these variations are hampered by appropriate ethical studies in men with suitable safe model compounds. Genetic analysis has allowed molecular identification of defects in well-known hyperbilirubinemias. However, full characterization of the specific functional roles of human UGTs and STs requires rigorous kinetic and molecular analyses of the role of each enzyme in vivo through the use of specific antibodies and inhibitors. This will leed to the better prediction of variation of xenobiotic glucuronidation and sulfation in man.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255555      PMCID: PMC1470020          DOI: 10.1289/ehp.97105s4739

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  81 in total

1.  Function and regulation of UDP-glucuronosyltransferase genes in health and liver disease: report of the Seventh International Workshop on Glucuronidation, September 1993, Pitlochry, Scotland.

Authors:  B Burchell; M W Coughtrie; P L Jansen
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

2.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

Authors:  K W Bock; D Schrenk; A Forster; E U Griese; K Mörike; D Brockmeier; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1994-08

Review 3.  Sulfonation in chemical carcinogenesis--history and present status.

Authors:  J A Miller
Journal:  Chem Biol Interact       Date:  1994-06       Impact factor: 5.192

4.  Mapping of two phenol sulphotransferase genes, STP and STM, to 16p: candidate genes for Batten disease.

Authors:  T P Dooley; H M Mitchison; P B Munroe; P Probst; M Neal; M J Siciliano; Z Deng; N A Doggett; D F Callen; R M Gardiner
Journal:  Biochem Biophys Res Commun       Date:  1994-11-30       Impact factor: 3.575

5.  Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation.

Authors:  S B Senafi; D J Clarke; B Burchell
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

6.  Minoxidil sulfation in the hair follicle.

Authors:  C A Baker; H Uno; G A Johnson
Journal:  Skin Pharmacol       Date:  1994

7.  Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s).

Authors:  H C Chou; N P Lang; F F Kadlubar
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

8.  Analysis of polymorphic variation in drug metabolism: III. Glucuronidation and sulfation of diflunisal in man.

Authors:  R J Herman; G R Loewen; D M Antosh; M R Taillon; S Hussein; R K Verbeeck
Journal:  Clin Invest Med       Date:  1994-08       Impact factor: 0.825

9.  Substance-dependent sex differences in the activation of benzylic alcohols to mutagens by hepatic sulfotransferases of the rat.

Authors:  H Glatt; K Pauly; H Frank; A Seidel; F Oesch; R G Harvey; G Werle-Schneider
Journal:  Carcinogenesis       Date:  1994-11       Impact factor: 4.944

10.  Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats.

Authors:  R A Barter; C D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  1994-09       Impact factor: 4.219

View more
  11 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: toward novel diagnostic targets.

Authors:  Mahmoud A Ghannoum; Pranab K Mukherjee; Richard J Jurevic; Mauricio Retuerto; Robert E Brown; Masoumeh Sikaroodi; Jennifer Webster-Cyriaque; Patrick M Gillevet
Journal:  OMICS       Date:  2011-07-13

Review 3.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

4.  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.

Authors:  T Andrew Clayton; David Baker; John C Lindon; Jeremy R Everett; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

Review 5.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.

Authors:  Dione Gardner-Stephen; Jean-Marie Heydel; Amit Goyal; Yuan Lu; Wen Xie; Tim Lindblom; Peter Mackenzie; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2004-03       Impact factor: 3.922

Review 7.  Protein-bound uremic toxins: new insight from clinical studies.

Authors:  Sophie Liabeuf; Tilman B Drüeke; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2011-07-20       Impact factor: 4.546

Review 8.  12th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals: susceptibility to environmental hazards.

Authors:  J C Barrett; H Vainio; D Peakall; B D Goldstein
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

Review 9.  Uremic Toxins and Vascular Dysfunction.

Authors:  Isabelle Six; Nadia Flissi; Gaëlle Lenglet; Loïc Louvet; Said Kamel; Marlène Gallet; Ziad A Massy; Sophie Liabeuf
Journal:  Toxins (Basel)       Date:  2020-06-18       Impact factor: 4.546

10.  Styrene trimer may increase thyroid hormone levels via down-regulation of the aryl hydrocarbon receptor (AhR) target gene UDP-glucuronosyltransferase.

Authors:  Yukie Yanagiba; Yuki Ito; Osamu Yamanoshita; Shu-Yun Zhang; Gen Watanabe; Kazuyoshi Taya; Chun Mei Li; Yuko Inotsume; Michihiro Kamijima; Frank J Gonzalez; Tamie Nakajima
Journal:  Environ Health Perspect       Date:  2008-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.